Denied Claims for New or Specialty Medications
The rapid pace of medical innovation has transformed the treatment of many serious diseases. New weight-loss medications, targeted cancer therapies, biologic drugs for autoimmune disorders, and other specialty medications are helping patients live longer, healthier lives. Unfortunately, these treatments are often among the most expensive prescription drugs on the market, making them frequent targets for insurance claim denials.
Health insurers commonly deny coverage for specialty medications by asserting that they are not medically necessary, are experimental or investigational, require additional prior authorization, or that a less expensive alternative should be tried first. While insurers are entitled to review claims and apply the terms of the insurance policy, they must also comply with California law and their contractual duty of good faith and fair dealing.
At Gianelli & Morris, we represent California policyholders whose health insurance claims have been wrongfully denied. When insurers place cost containment ahead of sound medical judgment or fail to conduct a fair evaluation of a claim, they may be acting in bad faith. Understanding why specialty medication claims are denied and when those denials may violate California law is an important first step in protecting your rights.
Why Specialty Medications Are Frequently Denied
Specialty medications are often significantly more expensive than traditional prescription drugs. Many are biologics, gene therapies, or highly targeted medications developed to treat complex medical conditions. Because of their cost, insurers typically subject these drugs to extensive utilization review before approving coverage.
Common examples include:
- GLP-1 medications prescribed for obesity or Type 2 diabetes, such as semaglutide and tirzepatide.
- Targeted oncology drugs used to treat specific cancers based on genetic or molecular testing.
- Biologic medications for rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, multiple sclerosis, and other autoimmune disorders.
- Specialty medications for rare diseases and genetic disorders.
These drugs often represent the current standard of care, yet their high cost makes them frequent subjects of insurance disputes.
Common Reasons Insurers Deny Specialty Drug Coverage
Insurance companies often rely on several recurring reasons for denying coverage.
One of the most common is an assertion that the medication is not medically necessary. The insurer may contend that another treatment should be tried first or that the patient’s condition does not meet its internal coverage criteria.
Another common basis for denial is that the medication is experimental or investigational. This frequently occurs with newer therapies that have recently entered the market, even when they have received approval from the U.S. Food and Drug Administration (FDA) and are supported by substantial clinical evidence.
Insurers may also deny claims because prior authorization requirements were not satisfied or because documentation is allegedly incomplete. In some cases, these denials result from administrative errors rather than legitimate coverage concerns.
Another frequent issue is step therapy, sometimes called “fail first” requirements. Under these policies, patients must first try one or more lower-cost medications before the insurer will approve the prescribed treatment. While step therapy can be appropriate in some circumstances, rigid application of these requirements may delay effective treatment or expose patients to unnecessary medical risks.
Weight-Loss Medications: A Rapidly Evolving Area
The recent popularity of GLP-1 medications has generated a sharp increase in insurance disputes. Many insurers have narrowed coverage for medications prescribed to treat obesity, even though obesity is recognized as a chronic medical condition associated with diabetes, heart disease, sleep apnea, and numerous other serious health problems. Some plans exclude weight-loss medications altogether. Others require patients to satisfy extensive prior authorization criteria, demonstrate participation in weight management programs, or meet strict body mass index (BMI) thresholds. Even when these requirements are met, insurers sometimes deny coverage by asserting that the requested medication is not medically necessary or that another treatment should be attempted first. As medical research continues to demonstrate the broader health benefits of GLP-1 medications, including reduced cardiovascular risks for certain patients, coverage standards continue to evolve.
Oncology Drugs and Precision Medicine
Cancer treatment has become increasingly individualized. Many modern oncology medications target specific genetic mutations or biomarkers identified through sophisticated diagnostic testing. These therapies often produce better outcomes than traditional chemotherapy for appropriate patients. Because these medications can cost tens of thousands of dollars each month, insurers frequently scrutinize requests for coverage. Problems arise when insurers rely on outdated treatment guidelines, fail to consider current medical literature, or apply generalized coverage policies that do not account for the patient’s unique diagnosis. A denial based on stale clinical information or incomplete review may prevent patients from receiving time-sensitive treatment during a critical stage of their illness.
Biologic Drugs and Autoimmune Diseases
Biologic medications have revolutionized treatment for many autoimmune conditions. Patients suffering from rheumatoid arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, lupus, and similar disorders often experience substantial improvements after beginning biologic therapy. However, these medications frequently require repeated prior authorizations, extensive documentation, and periodic reapproval. Insurers sometimes deny ongoing coverage despite evidence that the medication has been successful, arguing that additional information is needed or insisting that patients switch to a lower-cost alternative. Changing medications solely because of cost may place patients at risk of disease flare-ups, loss of symptom control, or serious complications.
Medical Necessity Requires Individualized Review
Many specialty medication disputes ultimately center on whether the treatment is medically necessary. California law requires insurers to conduct a reasonable investigation before denying coverage. Medical necessity determinations should be based on the patient’s individual medical condition, accepted standards of medical practice, current scientific evidence, and the treating physician’s clinical judgment. Unfortunately, insurers do not always conduct this individualized analysis. Instead, some rely heavily on internal coverage guidelines, utilization review software, or generalized treatment protocols that fail to account for the unique circumstances of the patient. Others selectively cite medical studies while ignoring more recent or higher-quality research supporting the requested treatment. In some instances, reviewers may rely on outdated literature that no longer reflects current standards of care. A fair evaluation requires consideration of all relevant evidence, not simply the evidence supporting denial.
When a Denial Reveals Insurance Bad Faith
Not every denial of specialty medication constitutes bad faith. Insurers may reasonably dispute coverage when legitimate questions exist regarding policy terms or medical evidence. However, California law requires insurers to investigate claims fairly, communicate honestly, and give equal consideration to the interests of their policyholders.
Some examples of when a denial may support a bad faith claim include when an insurer:
- Misrepresents policy provisions or coverage criteria.
- Fails to conduct a meaningful review of the medical evidence.
- Relies on outdated or incomplete clinical guidelines.
- Ignores the opinions of treating physicians without reasonable justification.
- Causes unnecessary delays by repeatedly requesting information it already possesses.
- Applies internal policies mechanically without considering the patient’s individual circumstances.
- Places cost savings ahead of a fair and objective evaluation of the claim.
When these practices result in the wrongful denial of medically necessary treatment, policyholders may have legal remedies beyond the insurer’s internal appeal process.
Legal Remedies Available to Policyholders
Depending on the circumstances, policyholders may first pursue internal appeals or an Independent Medical Review if the dispute involves medical necessity or allegations that a treatment is experimental or investigational. If the insurer’s conduct goes beyond a legitimate coverage dispute and reflects unreasonable claim handling, California law may permit a bad faith lawsuit. In appropriate cases, policyholders may be entitled to recover the benefits due under the policy, consequential damages resulting from the denial, damages for emotional distress, and, where the insurer acted with malice, oppression, or fraud, punitive damages under California Civil Code section 3294. Every case depends on its particular facts, but insurers cannot avoid liability simply because the treatment involved is expensive or relatively new.
Frequently Asked Questions
Can my health insurance company deny coverage for a new weight-loss medication?
Yes. Coverage depends on the terms of your policy and the insurer’s medical necessity criteria. However, denials must be based on a reasonable evaluation of your claim and applicable policy provisions.
What does “medical necessity” mean for specialty medications?
Generally, it means the medication is appropriate for diagnosing, treating, or managing your medical condition based on accepted standards of medical practice and your individual circumstances.
Can my insurer require me to try a cheaper drug first?
Many health plans use step therapy requirements, but those requirements must be applied consistently with applicable law and the terms of your policy. In some situations, exceptions may be appropriate.
What if my insurer says my medication is experimental or investigational?
You may have the right to appeal the decision or request an Independent Medical Review if the denial is based on medical necessity or experimental treatment. The insurer’s determination is not necessarily the final word.
When should I speak with an attorney about a denied medication claim?
If your insurer has repeatedly denied medically necessary treatment, caused unreasonable delays, or appears to have ignored the medical evidence supporting your claim, it may be appropriate to consult an attorney experienced in California insurance bad faith litigation.
Contact Gianelli & Morris
Specialty medications can be life-changing, and in many cases, life-saving. Insurance companies should not deny coverage simply because a treatment is expensive or requires careful review. When insurers fail to conduct a fair investigation, misapply medical necessity standards, or place financial considerations above patient care, they may be acting in bad faith.
At Gianelli & Morris, we have decades of experience representing California policyholders whose health insurance claims have been wrongfully denied. If your insurer has refused to cover a medically necessary specialty medication, our attorneys can evaluate your claim, explain your legal options, and determine whether the denial may constitute insurance bad faith.
Contact Gianelli & Morris today for a free consultation to discuss your case and learn how we can help protect your rights.
